Todd Parry, MD
Orthopaedic Surgery · Mesquite, NVNPI 1114905932
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Omnilife Science, Inc accounts for 86.9% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2020 at $18,241 and has fallen 99.7% since, to $53 in 2025.
Across 198 payments — averaging $218.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Omnilife Science, Inc$38K
- Pacira Therapeutics, Inc.$3K
- Corin USA$994
- Encore Medical, LP$482
- Stryker$448
- Imbed Biosciences Inc.$267
- plus $783 from 17 others
What the payments were for
- Consulting fees$19,87546%
- Travel & lodging$16,93539%
- Food & beverage$6,34815%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Omnilife Science, Inc | 30 | $37,501 |
| Pacira Therapeutics, Inc. | 109 | $2,691 |
| Corin USA | 5 | $994 |
| Encore Medical, LP | 3 | $482 |
| Stryker | 8 | $448 |
| Imbed Biosciences Inc. | 11 | $267 |
| Ortho Development Corporation | 3 | $211 |
| Endo Pharmaceuticals Inc. | 7 | $122 |
| Smith+Nephew | 3 | $73 |
| Ferring Pharmaceuticals Inc. | 4 | $50 |
| Johnson & Johnson | 1 | $45 |
| Vericel Corporation | 2 | $42 |
| Boston Scientific | 2 | $39 |
| Zimmer Biomet | 1 | $35 |
| Nevro Corp. | 1 | $29 |
| Heron Therapeutics, Inc. | 1 | $24 |
| Bioventus LLC | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $21 |
| Radius Health, Inc. | 1 | $16 |
| Integra Lifesciences Corporation | 1 | $15 |
| Pfizer | 1 | $13 |
| Davol Inc. | 1 | $12 |
| Orthofix Medical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,166 in reported general payments places this provider in the 85th percentile of 135 orthopaedic surgery providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 52 | $398 |
| Celecoxib | 19 | $299 |
| Ibuprofen | 11 | $220 |
| Cephalexin | 15 | $116 |
| Oxycodone Hcl | 12 | $112 |
| Tramadol Hcl | 21 | $106 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Mesquite
- Mark BarryLas Vegas$9.5M
- Erik KubiakLas Vegas$7.8M
- Russell NevinsLas Vegas$1.5M
- Vladimir SinkovLas Vegas$434K
- Robert TaitHenderson$365K
- Ronald HillockLas Vegas$275K
- Galen KamLas Vegas$270K
- Michael DaubsLas Vegas$215K
- Hilary MalcarneyReno$189K
- John BaldaufLas Vegas$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.